Physicians' Academy for Cardiovascular Education

Long-term Treatment With Evolocumab in Patients With Homozygous Familial Hypercholesterolaemia (HoFH): Interim Results from the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG) Study

June 19, 2015

Presentation prepared and held by Prof. Frederick Raal (University of Witwatersrand, Johannesburg, South Africa) in Clinical Breakthroughs session: Modifying LDL cholesterol to prevent CV events, Tuesday, May 26, 2015 during ISA2015 (Amsterdam, The Netherlands).

To view slides, click on images

ISA_LS_2015p_TAUSSIG_long_term_Raal.pdf (0,4MB)ISA_LS_2015p_TAUSSIG_long_term_Raal.pdf (0,4MB)